Roche posts results for lebrikizumab COPD trial; crovalimab pediatric aHUS study nears completion
Two Roche-sponsored studies updated this week: a completed Phase II COPD trial with results now posted, and an active Phase III pediatric aHUS trial with primary completion reached.
Roche had two clinical trial updates this week, one with newly posted results and one advancing toward study completion.
- Hoffmann-La Roche posted results for a completed Phase II trial of lebrikizumab in participants with chronic obstructive pulmonary disease and a history of exacerbations who were treated with inhaled corticosteroid and at least one long-acting bronchodilator inhaler medication.1 The study enrolled 309 participants and measured the primary outcome as change from baseline in pre-bronchodilator FEV1 at Week 12.1 Results were first posted on 2026-09-10, though the study itself completed back in November 2016.
- Hoffmann-La Roche, with collaborator Chugai Pharmaceutical, is running a Phase III single-arm study of crovalimab in pediatric patients with atypical hemolytic uremic syndrome2, known as COMMUTE-p. The trial, which enrolled 41 participants2, reached its primary completion date on 2025-07-04, with study completion estimated for 2029-05-19. Results were also posted this week, on 2026-09-09.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.